FIELD: pharmacology.
SUBSTANCE: invention relates to the field of pharmacology and is intended for the stabilization of latanoprost. The method for stabilizing latanoprost includes the step of mixing latanoprost, polyoxyl 40 hydrogenated castor oil (HCO-40) and sorbitol. Components are used in the declared quantities.
EFFECT: use of the invention makes it possible to stabilize latanoprost as part of an ophthalmic composition.
3 cl, 5 tbl, 10 ex, 8 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL COMPOSITION OF TAFLUPROST | 2021 |
|
RU2761625C2 |
| OIL-IN-WATER OPHTHALMIC EMULSIONS CONTAINING PROSTAGLANDINS | 2008 |
|
RU2460516C2 |
| OPHTHALMIC COMPOSITIONS CONTAINING PROSTAMIDE RELEASING NITROGEN OXIDE | 2019 |
|
RU2781022C2 |
| PHARMACEUTICAL COMPOSITIONS POSSESSING DESIRABLE BIOAVAILABILITY | 2009 |
|
RU2503453C2 |
| PHARMACEUTICAL DRUG CONTAINING PYRIDYLAMINOACETIC ACID | 2018 |
|
RU2776374C2 |
| MEDICINAL FORMS FOR EXTERNAL USE CONTAINING CYCLOSPORINE AND USE THEREOF | 2017 |
|
RU2747455C2 |
| MICROEMULSION COMPOSITIONS | 2019 |
|
RU2787998C1 |
| SELF-PRESERVED WATER PHARMACEUTICAL COMPOSITIONS | 2007 |
|
RU2436568C2 |
| STORAGE OF STABLE PREPARATION OF PROSTAGLANDIN | 2010 |
|
RU2482851C2 |
| DEPOT DRUG CONTAINING CITRIC ACID ESTER | 2016 |
|
RU2749952C2 |
